News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
FinancialContent Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
VivoSim Labs (NASDAQ: VIVS) is seeking stockholder approval for several key proposals at its virtual 2026 annual meeting on September 30, 2026. These include electing Class III directors, ratifying their auditor, an advisory vote on executive compensation, and crucially, approving a board-discretionary reverse stock …
The article provides a valuation analysis of VivoSim Labs Inc (VIVS), indicating that the stock is currently in the "Fair zone" based on its forward PS ratio. It details various financial metrics such as Price-to-Book (P/B) ratio, Free Cash Flow (FCF) yield, and compares …
This article provides a comprehensive overview of VivoSim Labs, Inc. (VIVS) stock, including its real-time price, historical data, and key financial metrics. It details the company's profile as a biotechnology firm specializing in 3D human tissue models for drug testing and development. The report …
VivoSim Labs announced it has regained compliance with Nasdaq's minimum stockholders’ equity rule following a $5.0 million milestone payment from Eli Lilly, the release of $1.0 million from escrow, and a $4.0 million financing completed in July 2026. The company reported approximately $10.1 million …
VivoSim Labs (NASDAQ:VIVS) has regained compliance with Nasdaq listing rules after receiving a $5.0 million milestone payment from Eli Lilly, a $1.0 million release from escrow, and completing a $4.0 million financing round. These financial infusions, which occurred in July 2026, increased the company's …
VivoSim Labs (VIVS) has announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders’ equity of $2.5 million. This compliance was achieved through several events in July 2026, including a $5.0 million milestone payment from Eli Lilly, a …
VivoSim Labs, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring a minimum stockholders’ equity of $2.5 million. This compliance was achieved through significant financial events in July 2026, including a $5.0 million milestone payment from Eli Lilly and Company, $1.0 …
VivoSim (VIVS) announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a $5.0 million milestone payment and $1.0 million escrow release from Eli Lilly, along with $3.6 million net proceeds from a financing. The company reported $10.1 million cash on hand …
VivoSim Labs issued 9,896,718 common shares between July 15 and July 31, 2026, due to the exercise of warrants. This issuance significantly increased the shares outstanding to 13,390,789 as of August 3, 2026, up from 3,194,295 on June 30, 2026. The warrant exercises followed …
VivoSim Labs (VIVS) announced that its 2026 Annual Meeting of Stockholders will take place on September 30, 2026, with August 13, 2026, designated as the record date. The meeting date was moved up by over 30 days compared to the previous year, necessitating an …
VivoSim Labs has announced its 2026 annual stockholders meeting will be held in San Diego on September 30, 2026. The meeting will include the election of directors, with a deadline for shareholder nominations set for August 9, 2026. This news brief was generated by …
This article provides a revenue breakdown for VivoSim Labs, Inc. (NASDAQ: VIVS), highlighting that the United States was the primary contributor to its revenue for the past two years. The company generated $131,000 USD from the US last year, a decrease from $144,000 USD …
VivoSim Labs (VIVS) received a notice from Nasdaq for failing to meet the Listing Rule 5550(b)(1) requiring $2.5 million in stockholders' equity. The company has 45 days to submit a compliance plan, with a possible extension, and trading remains unaffected. VivoSim Labs has reported …
This article provides a detailed financial overview of VivoSim Labs Ord Shs (VIVS), including its current stock price, market capitalization, key financial figures, and recent performance trends. It also lists technical indicators, moving averages, and major shareholders. The company's EPS and total revenue data …
VivoSim (Nasdaq: VIVS) has announced its first commercial sales in mainland China for its NAMkind™ liver and gastrointestinal toxicology screening and efficacy testing services. Secured through distributor Tekon, these initial paid programs with a Shanghai oncology biotech and a Chengdu pharmaceutical company represent a …
VivoSim Labs, Inc. announced its first commercial sales in China for its NAMkind™ toxicology screening and efficacy testing services, marking a significant expansion into the world's second-largest pharmaceutical market. The initial engagements involve a Shanghai-based oncology biotech and a Chengdu-based pharmaceutical company, secured through …
VivoSim Labs, Inc. has raised approximately $4.0 million through a private placement with a healthcare-focused institutional investor, selling shares and warrants at $0.85 per share. The company will use the net proceeds for working capital and general corporate purposes. This comes alongside recent news …
VivoSim Labs, INC. reported its fiscal year 2026 results, showing flat revenue at $0.13M compared to $0.14M in FY 2025. The company experienced a significant increase in net loss, reaching $13.843M from $2.488M the previous year, with diluted loss per share at $(5.35) versus …
VivoSim Labs Inc. announced a $4.0 million private placement with a single healthcare-focused institutional investor. The deal involves the sale of 4,705,883 shares of common stock and warrants at a combined price of $0.85 per share. Additionally, existing May 2024 warrants will have their …
VivoSim Labs has priced a $4 million private placement at $0.85 per share and warrant with a single healthcare-focused institutional investor. The deal includes 4,705,883 common shares and warrants, with the warrants becoming exercisable after shareholder approval and expiring in five years. Additionally, existing …
VivoSim Labs has secured $4.0 million through a private placement with a healthcare-focused institutional investor, involving the sale of common stock and warrants at $0.85 per share. Existing warrants will also be amended to lower their exercise price to $0.85, subject to shareholder approval. …
VivoSim Labs (NASDAQ:VIVS) has raised approximately $4.0 million through a private placement with a healthcare-focused institutional investor, selling shares and warrants at $0.85 per share. The company will use these proceeds for working capital and general corporate purposes. This funding follows recent positive developments, …
VivoSim Labs, Inc. has announced a securities purchase agreement with a healthcare-focused institutional investor for $4,000,000.55 in gross proceeds. This funding involves the sale of 4,705,883 common shares and pre-funded warrants, with an issue price and exercise price of $0.85 per share. The closing …
VivoSim Labs (VIVS) projects significant revenue growth for fiscal year 2027. The company's outlook indicates a strong financial performance in the coming years. This forecast suggests positive momentum for VIVS.
VivoSim Labs Inc. (NASDAQ: VIVS) shares surged on Wednesday due to a $5 million milestone payment received from Eli Lilly and Company (NYSE: LLY) and optimistic revenue guidance for FY2027, anticipating over 500% growth. The payment was triggered by the first patient being dosed …
Search by ticker symbol or company name and select a result to open its chart.